Evidence map›Paper›PMID 39726949›Full record

ArticleFrontiers in cardiovascular medicine2024

Changes in sST2 and NT-proBNP levels predict early cardiac arrhythmia in breast cancer patients treated with anthracycline-containing chemotherapies.

Cuncun Chen, Hui Zheng, Yanchun Wang, Ying Tong, Heng Zhang, Suhong Xie, Xiaolu Ma, Minglei Jiang, Zhiyun Gong, Tianqing Yan and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Cuncun ChenDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Hui ZhengDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Yanchun WangDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Ying TongDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Heng ZhangDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Suhong XieDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaolu MaDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Minglei JiangDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhiyun GongDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Tianqing YanDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Yanan TianDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Lin GuoDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Renquan LuDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cardiovascular biomarkers are crucial for monitoring cancer therapy-related cardiac toxicity, but the effects on early stage are still inadequate. To screen biomarkers in patients with breast cancer who receive anthracycline-containing chemotherapy, we studied the behavior of six biomarkers during chemotherapy and their association with chemotherapy-related cardiac toxicity. Methods: In a prospective cohort of 73 patients treated with anthracycline-containing chemotherapy, soluble suppression of tumorigenicity 2 (sST2), high-sensitivity cardiac troponin T, N-terminal pro-B-type natriuretic peptide (NT-proBNP), myoglobin, creatine kinase isoenzyme MB, and heart-fatty acid binding protein were measured at baseline, during chemotherapy cycle (C1-C6). According to whether arrhythmia occurred, patients were divided into two groups (healthy group or arrhythmias group), and basic clinical characteristics were collected and compared. Logistic regression analyses and receiver operating characteristic (ROC) curves were conducted to investigate the association between the changes in biomarkers and arrhythmia. Results: sST2 levels increased significantly from baseline to C1 ( Conclusions: Early changes in sST2 and NT-proBNP levels offer additive information for early arrhythmia prediction in breast cancer patients who receive anthracycline-containing chemotherapy.

Indexed as

arrhythmiacardiac toxicitychemotherapyNT-ProBNPsoluble ST2

Identifiers

PMID39726949
PMCPMC11669546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.